Enalees receives €500,000 subsidy

Partager / Share

Enalees received €500,000 subsidy


Additional funding will enable company, which specializes in veterinary diagnostic support, to strengthen and secure supply chain, develop product range and expand premises



Evry-Courcouronnes, France, October 11, 2022 – Enalees, a company specializing in the design, development and marketing of state-of-the-art rapid molecular diagnostic tests for the veterinary industry, today announces that it has been awarded a €500,000 ($489k) subsidy by the Île-de-France region as part of the France 2030 Investments for the Future Program (PIA). This funding will help finance a €1.1 million ($1.08M) project to strengthen the production supply chain of its infectious diseases diagnostic kits for domesticated animals (horses, dogs and cats).


In 2021, Enalees increased its production capacity by purchasing four automated freeze-dryers, so that it can perform this production phase in France. The company can now oversee quality control at all stages, from design through to manufacturing. This subsidy will help strengthen Enalees’ position in its existing market by supporting the development – potentially in partnership with other local players – of more ergonomic microtubes, better suited for use in the field. Enalees plans to expand its current 600 m2 premises at the Genopole research center (France) with a new 100 m2 laboratory for this new production line. The production team will be in place by the start of 2023.


This funding is vital for the growth of our business as it allows us to increase our manufacturing capacities. [CG1]explained Laurent Thiery, president and co-founder of Enalees.


Enalees’ molecular tests are used by veterinary professionals to help them diagnose infectious diseases quickly and accurately – both in their veterinary practices and in the field – without the need to send samples to an external laboratory. The tests are designed to detect DNA specific to the target pathogen and produce a result after just 30 minutes of analysis. This enables animals to be treated more quickly and, if necessary, placed in isolation.

 The global veterinary diagnostics market size was valued at $4.4 billion in 2018 and is projected to reach $9.5 billion by 2026, exhibiting a CAGR of 10% during the forecast period.


Thanks to this new funding, Enalees can now target new veterinary markets in Europe and beyond, where there is demand for more sensitive diagnostic tests. The company also plans to expand its range of diagnostic products for infectious diseases in domesticated animals (horses, dogs and cats).

About Enalees

Enalees develops rapid molecular diagnostic tests which enable veterinary professionals to diagnose infectious diseases – both in their veterinary practices and in the field – without the need to send samples to an external laboratory. Its team, which is primarily made up of doctors, engineers and biology technicians, has a particular focus on the development of innovative tests for domesticated animals (horses, dogs and cats).

Based on an isothermal amplification technique, the company’s products can detect
12 infectious diseases in horses, including Lyme disease (or Borreliosis) and equine influenza. To date, 80% of veterinary clinics in France use the technology. In 2021, the company also launched ten new tests for diagnosing infectious diseases in dogs and cats, making it the French market leader in veterinary LAMP PCR (Loop-mediated isothermal AMPlification Polymerase Chain Reaction). Enalees’ tests are currently available in Europe and will soon be launched in the US.

Founded in 2015, Enalees moved to the Genopole research center (France) in 2018, where it later set up its own lyophilization platform. This new facility enabled the company to increase its production capacity to over one million tests a year, including products for its own animal health business as well as custom tests for its partners.

Enalees now employs 32 staff. In 2021 it recorded €1.5 million ($1.47M) in sales, which equates to 66% growth.



About the Investments for the Future Program (PIA)

First launched ten years ago and overseen by the French General Secretariat for Investment as part of the French Prime Minister’s Office, the Investments for the Future Program (PIA) funds innovative projects that promote progress, sustainable growth and the creation of jobs for the future. The PIA supports the complete innovation life cycle, from the initial idea through to the launch of a new product or service, incorporating both the public and private sectors as well as economic, academic, national and European partners. Investment is subject to stringent criteria, open selection procedures and the principles of co-financing or return on investment for the state. The fourth PIA (PIA4) promises €20 billion in funding commitments between 2021–2025, €11 billion of which will support innovative projects under the France Relance economic recovery plan. The PIA will continue to support innovation in all its forms in the long term, so that France can strengthen its position in future growth sectors. In doing so, it will help to maintain its competitiveness, further its ecological transition, and promote the independence of its economy and organizations.

www.gouvernement.fr/secretariat-general-pour-l-investissement-sgpi      @SGPI_avenir

Investir l'avenir

Press and Analyst Contacts

Andrew Lloyd and Associates

Céline Gonzalez / Saffiyah Khalique

celine@ala.com / saffiyah@ala.com

UK: +44 1273 952 481

US: + 1 617 202 4491

Main Menu x